2023
Alterations in Immune Cell Composition during First-Line Therapy with Mosunetuzumab for Follicular or Marginal Zone Lymphoma
Olszewski A, Ollila T, Pelcovits A, Chorzalska A, Morgan J, McMahon J, Donnelly S, Huntington S, Matasar M, Reagan J, Milrod C, Dubielecka P. Alterations in Immune Cell Composition during First-Line Therapy with Mosunetuzumab for Follicular or Marginal Zone Lymphoma. Blood 2023, 142: 1651. DOI: 10.1182/blood-2023-181418.Peer-Reviewed Original ResearchEnd of therapyCytokine release syndromeMarginal zone lymphomaT cellsComplete responsePD1 expressionNK cellsB cellsEffector memory T cellsCheckpoint inhibitor combinationsExpression of LAG3Immune cell changesB-cell depletionFirst-line therapyExpansion of TregsT cell exhaustionMemory T cellsPrior chemotherapy exposureImmune cell subsetsImmune cell compositionPeripheral blood samplesMulticolor flow cytometrySignificant increaseTreatment-induced changesExhausted phenotype
2022
Renal effects of guideline‐directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology
Mullens W, Martens P, Testani JM, Tang WHW, Skouri H, Verbrugge FH, Fudim M, Iacoviello M, Franke J, Flammer AJ, Palazzuoli A, Barragan PM, Thum T, Marcos MC, Miró Ò, Rossignol P, Metra M, Lassus J, Orso F, Jankowska EA, Chioncel O, Milicic D, Hill L, Seferovic P, Rosano G, Coats A, Damman K. Renal effects of guideline‐directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology. European Journal Of Heart Failure 2022, 24: 603-619. PMID: 35239201, DOI: 10.1002/ejhf.2471.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic heart failureHeart failureRenal functionEjection fractionClinical practiceConsensus documentSodium-glucose cotransporter 2 inhibitorsGuideline-directed medical therapyReduced ejection fraction patientsEjection fraction patientsHeart Failure AssociationCotransporter 2 inhibitorsEuropean SocietyPharmacologic treatment optionsPoor renal functionDisease-modifying therapiesGood clinical practiceTreatment-induced changesDrug implementationHF drugsCardiology guidelinesESC guidelinesRenal effectsMedical therapyLifesaving therapyDimethyl Fumarate Reduces Inflammation in Chronic Active Multiple Sclerosis Lesions
Zinger N, Ponath G, Sweeney E, Nguyen TD, Lo CH, Diaz I, Dimov A, Teng L, Zexter L, Comunale J, Wang Y, Pitt D, Gauthier SA. Dimethyl Fumarate Reduces Inflammation in Chronic Active Multiple Sclerosis Lesions. Neurology Neuroimmunology & Neuroinflammation 2022, 9: e1138. PMID: 35046083, PMCID: PMC8771666, DOI: 10.1212/nxi.0000000000001138.Peer-Reviewed Original ResearchConceptsChronic active lesionsGlatiramer acetateRim lesionsHuman microgliaDimethyl fumarateMultiple sclerosisActive lesionsChronic active multiple sclerosis lesionsEffects of DMFActive multiple sclerosis lesionsClass III evidenceMarkers of inflammationRelapsing-remitting MSRetrospective observational studyQuantitative susceptibility mappingMultiple sclerosis lesionsActivation stateTreatment-induced changesMRI quantitative susceptibility mappingMicroglial activityGlial activityInflammatory activationMicroglial cellsObservational studyMS lesions
2020
1158-P: Cost-Effectiveness of Empagliflozin vs. Liraglutide as Second-Line Therapy for Type 2 Diabetes in the United States
REIFSNIDER O, PIMPLE P, STARGARDTER M, BRAND S, DESAI N, SHETTY S. 1158-P: Cost-Effectiveness of Empagliflozin vs. Liraglutide as Second-Line Therapy for Type 2 Diabetes in the United States. Diabetes 2020, 69 DOI: 10.2337/db20-1158-p.Peer-Reviewed Original ResearchBoehringer Ingelheim PharmaceuticalsUse of empagliflozinT2D patientsCardiovascular diseaseAdverse eventsUnited Kingdom Prospective Diabetes Study (UKPDS) risk equationsGLP-1 receptor agonistsT2D-related complicationsSecond-line therapyType 2 diabetesClinical trial resultsTreatment-induced changesBackground metforminCVD subgroupsCV deathRenal outcomesHazard ratioClinical outcomesSGLT2 inhibitorsCVS CaremarkMyocardial infarctionReceptor agonistSpouse/partnerImproved outcomesDrug classes
2018
Early B cell changes predict autoimmunity following combination immune checkpoint blockade
Das R, Bar N, Ferreira M, Newman AM, Zhang L, Bailur JK, Bacchiocchi A, Kluger H, Wei W, Halaban R, Sznol M, Dhodapkar MV, Dhodapkar KM. Early B cell changes predict autoimmunity following combination immune checkpoint blockade. Journal Of Clinical Investigation 2018, 128: 715-720. PMID: 29309048, PMCID: PMC5785243, DOI: 10.1172/jci96798.Peer-Reviewed Original ResearchConceptsCombination checkpoint blockadeB cell changesB cellsCheckpoint blockadeCell changesCombination immune checkpoint blockadeB-cell receptor sequencingRisk of irAEsImmune checkpoint blockadeCell receptor sequencingB cell activationTreatment-induced changesCCB therapyAdverse eventsPD1 expressionPD1 receptorGrade 3PatientsCell activationEarly changesSingle-cell RNA sequencingTherapyPreemptive strategyCancer therapyIrAEs
2012
Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference
Toi M, Benson JR, Winer EP, Forbes JF, von Minckwitz G, Golshan M, Robertson JF, Sasano H, Cole BF, Chow LW, Pegram MD, Han W, Huang CS, Ikeda T, Kanao S, Lee ES, Noguchi S, Ohno S, Partridge AH, Rouzier R, Tozaki M, Sugie T, Yamauchi A, Inamoto T. Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference. Breast Cancer Research And Treatment 2012, 136: 919-926. PMID: 23143284, DOI: 10.1007/s10549-012-2333-9.Peer-Reviewed Original ResearchConceptsPreoperative systemic therapyCore needle biopsyMulti-gene signatureSystemic therapyConsensus conferenceHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Fine needle aspiration cytologyEarly breast cancerGrowth factor receptor 2Node-positive casesLikelihood of patientsIndividualized treatment regimensKi67 labeling indexNeedle aspiration cytologyFactor receptor 2Treatment-induced changesCell proliferative activityLymph node diagnosisAxillary surgeryLocoregional managementNodal statusLocal therapySurgical treatmentTreatment algorithm
1999
Effect of long-term beta-carotene and vitamin A on serum cholesterol and triglyceride levels among participants in the Carotene and Retinol Efficacy Trial (CARET)
Redlich C, Chung J, Cullen M, Blaner W, Van Bennekum A, Berglund L. Effect of long-term beta-carotene and vitamin A on serum cholesterol and triglyceride levels among participants in the Carotene and Retinol Efficacy Trial (CARET). Atherosclerosis 1999, 145: 425-432. PMID: 10488974, DOI: 10.1016/s0021-9150(99)00266-x.Peer-Reviewed Original ResearchConceptsSerum triglyceride levelsHigh-density lipoproteinActive treatment groupLDL cholesterol levelsTriglyceride levelsCancer chemoprevention trialsCholesterol levelsSmall nonsignificant increaseCARET participantsCardiovascular mortalityTreatment groupsNonsignificant increaseLow-density lipoprotein cholesterol levelsLung cancer chemoprevention trialsRetinol Efficacy TrialActive treatment armsLipoprotein cholesterol levelsLung cancer mortalityLong-term supplementationActive intervention groupTreatment-induced changesSerum lipidsChemoprevention trialsHDL cholesterolActive treatmentEffect of long-term beta-carotene and vitamin A on serum cholesterol and triglyceride levels among participants in the Carotene and Retinol Efficacy Trial (CARET)
Redlich C, Chung J, Cullen M, Blaner W, Van Bennekum A, Berglund L. Effect of long-term beta-carotene and vitamin A on serum cholesterol and triglyceride levels among participants in the Carotene and Retinol Efficacy Trial (CARET). Atherosclerosis 1999, 143: 427-434. PMID: 10217373, DOI: 10.1016/s0021-9150(98)00303-7.Peer-Reviewed Original ResearchConceptsSerum triglyceride levelsHigh-density lipoproteinActive treatment groupLDL cholesterol levelsTriglyceride levelsCancer chemoprevention trialsCholesterol levelsSmall nonsignificant increaseCARET participantsCardiovascular mortalityTreatment groupsNonsignificant increaseLow-density lipoprotein cholesterol levelsLung cancer chemoprevention trialsRetinol Efficacy TrialActive treatment armsLipoprotein cholesterol levelsLung cancer mortalityLong-term supplementationActive intervention groupTreatment-induced changesSerum lipidsChemoprevention trialsHDL cholesterolActive treatment
1984
Lithium transport across squid axon membrane
Ehrlich B, Russell J. Lithium transport across squid axon membrane. Brain Research 1984, 311: 141-143. PMID: 6091848, DOI: 10.1016/0006-8993(84)91406-9.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply